*ST Eye Medicine (600671.SH): As of April 19, 2024, the number of shareholders of the company was 6,305
Gelonghui, April 30丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of April 19, 2024, the number of shareholders of the company was 6,305.
*ST Eye Medicine (600671.SH) announced first-quarter results with a net loss of 9.722,800 yuan
Zhitong Finance App News, *ST Pharmaceutical (600671.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 383.34 million yuan, an increase of 72.25% over the previous year; net loss attributable to shareholders of listed companies was 9.722,800 yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 10.7525 million yuan; basic loss per share.
*ST Eye Medicine (600671.SH): Number of shareholders as of April 10, 2024 is 6545
Gelonghui, April 15丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of April 10, 2024, the number of shareholders was 6,545.
*ST Eye Medicine (600671.SH): Number of shareholders as of January 31, 2024 is 6,659
Gelonghui, Feb. 2丨*ST Eye Medicine (600671.SH) said on an interactive platform that as of January 31, 2024, the number of shareholders was 6,659.
*ST Eye Medicine (600671.SH): Expected net loss of 32.245,500 yuan to 40.245,500 yuan in 2023
Gelonghui announced on January 29丨*ST Eye Medicine (600671.SH) announced that it is expected to achieve net profit attributable to shareholders of listed companies of -40.245,500 yuan to -32.2455 million yuan in 2023. Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses for the year 2023 is estimated to be 41.134 million yuan to -33.1340 million yuan. According to preliminary estimates by the company's finance department, the company's annual revenue in 2023 is estimated to be RMB 116 million to RMB 126.0 million; it is estimated that the company's 2023 annual deductions and main operations
*ST Eye Medicine (600671.SH): Shareholder Yuanjia Medical voluntarily promises not to reduce the company's shares within 18 months
Gelonghui (600671.SH) announced on November 1, *ST Pharmaceutical () announced that, based on confidence in Tianmu Pharmaceutical's future development prospects and recognition of long-term investment value, Yuanjia Medical, a shareholder holding 12.36% of the company, made a voluntary commitment not to transfer its Tianmu Pharmaceutical shares within the next 18 months from November 1, 2023 (November 1, 2023 to April 30, 2025), including shares added during the commitment period due to capital reserves, distribution of stock dividends, allocations, and additional issuance of shares.
[Instant Analysis of BT Financial Report] *ST Meyao 2023 Interim Report: Debt Ratio Rises, Net Assets Turned Negative, Performance Pressure Increased
*ST Pharmaceutical (stock code: 600671) is a company mainly engaged in pharmaceutical manufacturing, drug distribution, traditional Chinese medicine diagnosis and treatment, and health. Its products include amoxicillin clavulanate potassium tablets, dendrobium officinale health products, etc., and the sales area is mainly concentrated in East China and South China. However, judging from its 2023 interim report, the company is facing some financial pressure. First, judging from the balance ratio, *ST's balance ratio rose from 98.51% at the beginning of the period to 107.47% at the end of the period. This indicates that the company's debt pressure has increased, and its liabilities have exceeded total assets, which makes up the company's operations
*ST Eye Drug (600671.SH): New official seal and contract-specific seal introduced
*ST Eye Drug (600671.SH) issued an announcement. The company is seriously worn and worn due to frequent use of official seals and special contract seals,...
*ST Eye Medicine (600671.SH): Elects Liu Jiayong as Chairman
*ST Eye Drug (600671.SH) announced that the company will hold its 11th session on October 13, 2023...
*ST Eye Medicine (600671.SH): Appoints Xu Xuyu as the company's general manager (president)
*ST Eye Drug (600671.SH) issued an announcement, was nominated by the company's chairman, and reviewed by the nomination committee of the board of directors...
*ST Eye Drug (600671.SH) released semi-annual results, with a net loss of 23.42 million yuan
*ST Pharmaceutical (600671.SH) disclosed the 2023 semi-annual report. The company achieved 509 revenue during the reporting period...
*ST Eye Medicine (600671.SH): Yu Jie resigns as Chief Financial Officer due to personal reasons
Gelonghui, August 21丨*ST Eye Medicine (600671.SH) announced that the company's board of directors recently received a written resignation report from Yu Jie, the company's financial director. Yu Jie resigned as the company's financial director due to personal reasons. After his resignation, the company will make separate arrangements. After Yu Jie resigned, before the company appointed a new financial director, in order to ensure the normal development of the company's various tasks, the company designated general manager Liu Bo to temporarily assume the duties of financial director for the period until the new financial director was appointed.
*ST Pharmaceutical (600671.SH): It is proposed to raise an additional capital of 278 million yuan from Huilong Huazeding to supplement liquidity and repay debts
Gelonghui, August 21丨*ST Pharmaceutical (600671.SH) announced that the company plans to issue shares to Qingdao Huilong Huase Investment Co., Ltd. (“Huilong Huase”). The number of shares to be issued is 365.33,54 million shares, and the total capital raised is about 278 million yuan. After deducting related issuance expenses, it is intended to be used by Tianmu Pharmaceutical to supplement liquidity and repay debts.
*ST Eye Medicine (600671.SH): The Finance Bureau of Laoshan District, Qingdao will become the actual controller of the company
Gelonghui August 21丨*ST Pharmaceutical (600671.SH) announced that on August 18, 2023, Yonghua Xinhuarui Culture Development Co., Ltd. (“Yonghua Xinhuarui” or “transferee”) signed a “share transfer agreement” with the company shareholders Qingdao Huilong Huase Investment Co., Ltd. (“Huilong Huase” or “Assignee 1”) and Qingdao Yuanjia Medical Technology Co., Ltd. (“Yuanjia Medical” or “Assignee 2”), respectively. Yongxin Xinhuarui plans to transfer the company's 9.72 million shares (accounting for 7.98% of the company's total share capital) to Huilong Huase. Yongxin Xinhuarui will hold 1,5045,900 shares of the company
*ST Eye Drug (600671.SH) and related personnel received a warning letter from the Zhejiang Securities Regulatory Bureau
According to the Zhitong Finance App, *ST Eye Medicine (600671.SH) announced that the company recently received the “Decision on Issuing Warning Letter Measures against Hangzhou Tianmusan Pharmaceutical Co., Ltd. and related responsible persons” (“Warning Letter”) issued by the Zhejiang Regulatory Bureau of the China Securities Regulatory Commission (“Zhejiang Securities Regulatory Bureau”). According to reports, the Zhejiang Securities Regulatory Bureau discovered that the company had the following problems during supervision: 1. The company's reporting of projects under construction in 2020-2022 was incorrect and there was a problem of underrecording depreciation. 2. The company did not promptly disclose the bank account freeze situation. 3. The company did not promptly disclose the holding subsidiary Zhejiang Tianmu Biotech
KuaiBao: ST eye medicine (600671) the falling limit is closed at 10:14 on January 18th.
January 18 intraday news, 10:14 ST eye drug (600671) closed the limit board. The current price is 9.48, down 5.01%. It belongs to the plate of traditional Chinese medicine is currently falling. Lead the stock to rise for the essence of pharmaceuticals. The main indicators and industry rankings of ST are as follows: ST Pharmaceuticals (600671) Stock profile: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
KuaiBao: ST eye medicine (600671) seal the trading limit at 09:59 on January 11th.
January 11 intraday news, 09:59 ST eye drug (600671) sealed the trading limit. The current price is 10.59, up 4.96%. It belongs to the plate of traditional Chinese medicine is on the rise. The leading stock is auspicious Pharmaceutical Holdings. The main indicators and industry rankings of ST are as follows: ST Pharmaceuticals (600671) Stock profile: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
Review of the daily limit board: the contraction of the Prev index rebounded and rose 0.39%. More than 3000 stocks in the two markets rose.
January 10 news, the three major indices opened low after the bottom turned red, the index returned to 3100 points, once fell more than 1%, the plate, COVID-19 test plate higher, digital currency lower, meta-universe concept performance, salt lake lithium plate strong. In the afternoon, the three major indexes fell and turned green again, with northward capital inflows of nearly 9 billion yuan. in terms of plates, the concept of meta-universe rebounded and the real estate plate moved higher. Overall, the market as a whole is in a weak and volatile pattern, the long-short game is fierce, individual stocks rise more and fall less, and the money-making effect is general. By the end of the day, the Prev was up 0.39% at 3593.52 points, a deal.
News flash: the limit of ST drugs was reported at 10.09 yuan.
China Finance Online Co Ltd net January 10 news, today ST eye drug opened at 9.53 yuan, as of 11:00, the stock rose 4.99% to 10.09 yuan, sealed the limit. Yesterday (2022-01-07) the net outflow of the stock was-2.8318 million yuan, the main net outflow was-953700 yuan, the net outflow of the single unit was-965100 yuan, and the net outflow of retail investors was-913000 yuan. (to view the real-time capital flow, please click) in the last month, ST eye drugs have been on the list of dragons and tigers for a total of 0 times, indicating that ST eye drugs are sexually inactive. (for more enquiries on the Dragon and Tiger list, please
KuaiBao: ST eye medicine (600671) blocking the trading limit at 10:54 on January 10th
January 10 intraday news, 10:54 ST eye drug (600671) sealed the trading board. The current price is 10.09, up 4.99%. It belongs to the plate of traditional Chinese medicine is on the rise. Lead the stock to rise for the pharmaceutical industry of all living beings. The main indicators and industry rankings of ST are as follows: ST Pharmaceuticals (600671) Stock profile: this article is compiled by Securities Star data Center according to public data, and does not constitute investment opinions or suggestions. If you have any questions, please contact us.
No Data